Approved HCV Drugs
Approved HCV Drugs
AASLD 2014: Sofosbuvir/ Ledipasvir + Ribavirin Cures Most Post-Transplant HCV Recurrence
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 25 November 2014 00:00
- Written by Liz Highleyman
An interferon-free regimen of sofosbuvir plus ledipasvir (Harvoni) taken with ribavirin for 12 or 24 weeks led to sustained virological response in nearly all HCV genotype 1patients with fibrosis or less-advanced liver cirrhosis, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston. Response rates fell for people with more severe cirrhosis and signs of liver decompensation, but still a majority were cured.
AASLD 2014: Sofosbuvir + Simeprevir Shows Good Results in Real-World Use
- Details
- Category: Approved HCV Drugs
- Published on Friday, 21 November 2014 00:00
- Written by Liz Highleyman
Regimens containing sofosbuvir (Sovaldi) -- including sofosbuvir plus simeprevir (Olysio) -- work well for people with hepatitis C genotype 1 in real-world use, which to date has included some of the patients most urgently in need of treatment at the dawn of the interferon-free era, according to a pair of presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston. Sofosbuvir plus ribavirin alone is highly effective for people with genotype 2.
AASLD 2014: Grazoprevir/ Elbasvir Combo Shows High Cure Rates, Including Cirrhotics and Coinfected
- Details
- Category: Approved HCV Drugs
- Published on Thursday, 13 November 2014 00:00
- Written by Liz Highleyman
An all-oral regimen of grazoprevir (MK-5172) and elbasvir (MK-8742), taken with or without ribavirin for 12 weeks, demonstrated high sustained virological response rates for treatment-naive and treatment-experienced genotype 1 hepatitis C patients, including people with liver cirrhosis and HIV/HCV coinfection, according to research presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston and published simultaeously in The Lancet. However, pushing treatment duration with this combination plus sofosbuvir down to 4 or 6 weeks raised the risk of treatment failure.
AASLD 2014: AbbVie 3D Regimen and Sofosbuvir/ Ribavirin Show High Cure Rates for HIV/HCV Coinfection
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 19 November 2014 00:00
- Written by Liz Highleyman
AbbVie's 3D regimen (paritaprevir/ombitasvir/ritonavir plus dasabuvir) with ribavirin for 12 weeks and Gilead Science's sofosbuvir (Sovaldi) plus ribavirin for 24 weeks both produced good sustained virological response rates for most patients with HIV and hepatitis C virus (HCV) coinfection, according to studies presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston.
AASLD 2014: Sofosbuvir/ Ledipasvir + Ribavirin Highly Effective for People with Decompensated Cirrhosis
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 12 November 2014 00:00
- Written by Liz Highleyman
An oral regimen of sofosbuvir/ledipasvir (Harvoni) plus ribavirin taken for 12 weeks cured most hepatitis C patients with decompensated cirrhosis, the most advanced stage of liver disease, according to a presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston. Sustained response was associated with improved liver function in most patients.
More Articles...
- AASLD 2014: Sofosbuvir/Ledipasvir and AbbVie 2D Cure Most People with HCV Genotype 4
- AASLD 2014: Sustained Response to HCV Treatment Reduces Mortality, Liver Cancer, Liver Transplants
- AASLD 2014: Sofosbuvir/Ledipasvir Cures Nearly All Genotype 1 HIV/HCV Coinfected Patients
- ICAAC 2014: Telaprevir and Boceprevir Have Limited Efficacy in Real-world Use
Web Design and Development by